PMC:7340597 / 25705-27127 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid_Glycan-Motif-Structure

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T23","span":{"begin":1310,"end":1323},"obj":"https://glytoucan.org/Structures/Glycans/G93424OB"}],"text":"Recently there is increasing awareness and concern for development of secondary infection in COVID patients e.g. invasive aspergillus co-infection, a contra-indication for (long-term) systemic steroid therapy. Criteria and risk factors for invasive pulmonary aspergillosis are well defined in immunocompromised populations. Furthermore it is a well known complication of severe influenza pneumonia with reported incidences of 19% in ICU patients admitted for influenza related acute respiratory failure with high mortality rates [33]. In COVID-19 associated pulmonary aspergillosis (CAPA) case definition is absent, although recently an expert panel proposed a classification for IAPA, which was used to classify CAPA [14]. Pathophysiology of CAPA consists of lung damage with bilateral alveolar-interstitial damage due to viral replication and cytokine storm in combination with marked low T-lymphocytes CD4 + T and CD8 + T cells [27]. Secondary infection due to lung tissue damage develop within a median of 17 days [34]. CAPA data are scarce but increasingly reported, although histological confirmation is still absent [9,13,35,36]. Of the first 31 COVID-19 patients admitted to our ICU, six where highly suspected for COVID-19 associated pulmonary aspergillosis (CAPA) [9]. In this case series, BAL fluid galactomannan was positive in six out of the seven cases, concluding in the clinical diagnosis of probable CAPA."}

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T140","span":{"begin":760,"end":764},"obj":"Body_part"},{"id":"T141","span":{"begin":787,"end":795},"obj":"Body_part"},{"id":"T142","span":{"begin":845,"end":853},"obj":"Body_part"},{"id":"T143","span":{"begin":891,"end":904},"obj":"Body_part"},{"id":"T144","span":{"begin":925,"end":930},"obj":"Body_part"},{"id":"T145","span":{"begin":964,"end":968},"obj":"Body_part"},{"id":"T146","span":{"begin":969,"end":975},"obj":"Body_part"}],"attributes":[{"id":"A140","pred":"fma_id","subj":"T140","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A141","pred":"fma_id","subj":"T141","obj":"http://purl.org/sig/ont/fma/fma264783"},{"id":"A142","pred":"fma_id","subj":"T142","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A143","pred":"fma_id","subj":"T143","obj":"http://purl.org/sig/ont/fma/fma62870"},{"id":"A144","pred":"fma_id","subj":"T144","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A145","pred":"fma_id","subj":"T145","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A146","pred":"fma_id","subj":"T146","obj":"http://purl.org/sig/ont/fma/fma9637"}],"text":"Recently there is increasing awareness and concern for development of secondary infection in COVID patients e.g. invasive aspergillus co-infection, a contra-indication for (long-term) systemic steroid therapy. Criteria and risk factors for invasive pulmonary aspergillosis are well defined in immunocompromised populations. Furthermore it is a well known complication of severe influenza pneumonia with reported incidences of 19% in ICU patients admitted for influenza related acute respiratory failure with high mortality rates [33]. In COVID-19 associated pulmonary aspergillosis (CAPA) case definition is absent, although recently an expert panel proposed a classification for IAPA, which was used to classify CAPA [14]. Pathophysiology of CAPA consists of lung damage with bilateral alveolar-interstitial damage due to viral replication and cytokine storm in combination with marked low T-lymphocytes CD4 + T and CD8 + T cells [27]. Secondary infection due to lung tissue damage develop within a median of 17 days [34]. CAPA data are scarce but increasingly reported, although histological confirmation is still absent [9,13,35,36]. Of the first 31 COVID-19 patients admitted to our ICU, six where highly suspected for COVID-19 associated pulmonary aspergillosis (CAPA) [9]. In this case series, BAL fluid galactomannan was positive in six out of the seven cases, concluding in the clinical diagnosis of probable CAPA."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T85","span":{"begin":760,"end":764},"obj":"Body_part"},{"id":"T86","span":{"begin":964,"end":968},"obj":"Body_part"},{"id":"T87","span":{"begin":969,"end":975},"obj":"Body_part"}],"attributes":[{"id":"A85","pred":"uberon_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A86","pred":"uberon_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A87","pred":"uberon_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"Recently there is increasing awareness and concern for development of secondary infection in COVID patients e.g. invasive aspergillus co-infection, a contra-indication for (long-term) systemic steroid therapy. Criteria and risk factors for invasive pulmonary aspergillosis are well defined in immunocompromised populations. Furthermore it is a well known complication of severe influenza pneumonia with reported incidences of 19% in ICU patients admitted for influenza related acute respiratory failure with high mortality rates [33]. In COVID-19 associated pulmonary aspergillosis (CAPA) case definition is absent, although recently an expert panel proposed a classification for IAPA, which was used to classify CAPA [14]. Pathophysiology of CAPA consists of lung damage with bilateral alveolar-interstitial damage due to viral replication and cytokine storm in combination with marked low T-lymphocytes CD4 + T and CD8 + T cells [27]. Secondary infection due to lung tissue damage develop within a median of 17 days [34]. CAPA data are scarce but increasingly reported, although histological confirmation is still absent [9,13,35,36]. Of the first 31 COVID-19 patients admitted to our ICU, six where highly suspected for COVID-19 associated pulmonary aspergillosis (CAPA) [9]. In this case series, BAL fluid galactomannan was positive in six out of the seven cases, concluding in the clinical diagnosis of probable CAPA."}

LitCovid-PubTator

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T233","span":{"begin":148,"end":149},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T234","span":{"begin":342,"end":343},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T235","span":{"begin":659,"end":660},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T236","span":{"begin":760,"end":764},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T237","span":{"begin":760,"end":764},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T238","span":{"begin":905,"end":908},"obj":"http://purl.obolibrary.org/obo/PR_000001004"},{"id":"T239","span":{"begin":917,"end":920},"obj":"http://purl.obolibrary.org/obo/CLO_0053438"},{"id":"T240","span":{"begin":923,"end":930},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T241","span":{"begin":932,"end":934},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T242","span":{"begin":964,"end":968},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T243","span":{"begin":964,"end":968},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T244","span":{"begin":998,"end":999},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T245","span":{"begin":1019,"end":1021},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"}],"text":"Recently there is increasing awareness and concern for development of secondary infection in COVID patients e.g. invasive aspergillus co-infection, a contra-indication for (long-term) systemic steroid therapy. Criteria and risk factors for invasive pulmonary aspergillosis are well defined in immunocompromised populations. Furthermore it is a well known complication of severe influenza pneumonia with reported incidences of 19% in ICU patients admitted for influenza related acute respiratory failure with high mortality rates [33]. In COVID-19 associated pulmonary aspergillosis (CAPA) case definition is absent, although recently an expert panel proposed a classification for IAPA, which was used to classify CAPA [14]. Pathophysiology of CAPA consists of lung damage with bilateral alveolar-interstitial damage due to viral replication and cytokine storm in combination with marked low T-lymphocytes CD4 + T and CD8 + T cells [27]. Secondary infection due to lung tissue damage develop within a median of 17 days [34]. CAPA data are scarce but increasingly reported, although histological confirmation is still absent [9,13,35,36]. Of the first 31 COVID-19 patients admitted to our ICU, six where highly suspected for COVID-19 associated pulmonary aspergillosis (CAPA) [9]. In this case series, BAL fluid galactomannan was positive in six out of the seven cases, concluding in the clinical diagnosis of probable CAPA."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T124","span":{"begin":193,"end":200},"obj":"Chemical"},{"id":"T125","span":{"begin":1300,"end":1303},"obj":"Chemical"},{"id":"T126","span":{"begin":1310,"end":1323},"obj":"Chemical"}],"attributes":[{"id":"A124","pred":"chebi_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/CHEBI_35341"},{"id":"A125","pred":"chebi_id","subj":"T125","obj":"http://purl.obolibrary.org/obo/CHEBI_64198"},{"id":"A126","pred":"chebi_id","subj":"T126","obj":"http://purl.obolibrary.org/obo/CHEBI_27680"}],"text":"Recently there is increasing awareness and concern for development of secondary infection in COVID patients e.g. invasive aspergillus co-infection, a contra-indication for (long-term) systemic steroid therapy. Criteria and risk factors for invasive pulmonary aspergillosis are well defined in immunocompromised populations. Furthermore it is a well known complication of severe influenza pneumonia with reported incidences of 19% in ICU patients admitted for influenza related acute respiratory failure with high mortality rates [33]. In COVID-19 associated pulmonary aspergillosis (CAPA) case definition is absent, although recently an expert panel proposed a classification for IAPA, which was used to classify CAPA [14]. Pathophysiology of CAPA consists of lung damage with bilateral alveolar-interstitial damage due to viral replication and cytokine storm in combination with marked low T-lymphocytes CD4 + T and CD8 + T cells [27]. Secondary infection due to lung tissue damage develop within a median of 17 days [34]. CAPA data are scarce but increasingly reported, although histological confirmation is still absent [9,13,35,36]. Of the first 31 COVID-19 patients admitted to our ICU, six where highly suspected for COVID-19 associated pulmonary aspergillosis (CAPA) [9]. In this case series, BAL fluid galactomannan was positive in six out of the seven cases, concluding in the clinical diagnosis of probable CAPA."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T64","span":{"begin":240,"end":272},"obj":"Phenotype"},{"id":"T65","span":{"begin":388,"end":397},"obj":"Phenotype"},{"id":"T66","span":{"begin":483,"end":502},"obj":"Phenotype"},{"id":"T67","span":{"begin":845,"end":859},"obj":"Phenotype"}],"attributes":[{"id":"A64","pred":"hp_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A65","pred":"hp_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A66","pred":"hp_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/HP_0002878"},{"id":"A67","pred":"hp_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/HP_0033041"}],"text":"Recently there is increasing awareness and concern for development of secondary infection in COVID patients e.g. invasive aspergillus co-infection, a contra-indication for (long-term) systemic steroid therapy. Criteria and risk factors for invasive pulmonary aspergillosis are well defined in immunocompromised populations. Furthermore it is a well known complication of severe influenza pneumonia with reported incidences of 19% in ICU patients admitted for influenza related acute respiratory failure with high mortality rates [33]. In COVID-19 associated pulmonary aspergillosis (CAPA) case definition is absent, although recently an expert panel proposed a classification for IAPA, which was used to classify CAPA [14]. Pathophysiology of CAPA consists of lung damage with bilateral alveolar-interstitial damage due to viral replication and cytokine storm in combination with marked low T-lymphocytes CD4 + T and CD8 + T cells [27]. Secondary infection due to lung tissue damage develop within a median of 17 days [34]. CAPA data are scarce but increasingly reported, although histological confirmation is still absent [9,13,35,36]. Of the first 31 COVID-19 patients admitted to our ICU, six where highly suspected for COVID-19 associated pulmonary aspergillosis (CAPA) [9]. In this case series, BAL fluid galactomannan was positive in six out of the seven cases, concluding in the clinical diagnosis of probable CAPA."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T11","span":{"begin":823,"end":840},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T12","span":{"begin":823,"end":840},"obj":"http://purl.obolibrary.org/obo/GO_0019058"}],"text":"Recently there is increasing awareness and concern for development of secondary infection in COVID patients e.g. invasive aspergillus co-infection, a contra-indication for (long-term) systemic steroid therapy. Criteria and risk factors for invasive pulmonary aspergillosis are well defined in immunocompromised populations. Furthermore it is a well known complication of severe influenza pneumonia with reported incidences of 19% in ICU patients admitted for influenza related acute respiratory failure with high mortality rates [33]. In COVID-19 associated pulmonary aspergillosis (CAPA) case definition is absent, although recently an expert panel proposed a classification for IAPA, which was used to classify CAPA [14]. Pathophysiology of CAPA consists of lung damage with bilateral alveolar-interstitial damage due to viral replication and cytokine storm in combination with marked low T-lymphocytes CD4 + T and CD8 + T cells [27]. Secondary infection due to lung tissue damage develop within a median of 17 days [34]. CAPA data are scarce but increasingly reported, although histological confirmation is still absent [9,13,35,36]. Of the first 31 COVID-19 patients admitted to our ICU, six where highly suspected for COVID-19 associated pulmonary aspergillosis (CAPA) [9]. In this case series, BAL fluid galactomannan was positive in six out of the seven cases, concluding in the clinical diagnosis of probable CAPA."}

LitCovid-PD-GlycoEpitope

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T21","span":{"begin":1310,"end":1323},"obj":"GlycoEpitope"}],"attributes":[{"id":"A21","pred":"glyco_epitope_db_id","subj":"T21","obj":"http://www.glycoepitope.jp/epitopes/EP0510"}],"text":"Recently there is increasing awareness and concern for development of secondary infection in COVID patients e.g. invasive aspergillus co-infection, a contra-indication for (long-term) systemic steroid therapy. Criteria and risk factors for invasive pulmonary aspergillosis are well defined in immunocompromised populations. Furthermore it is a well known complication of severe influenza pneumonia with reported incidences of 19% in ICU patients admitted for influenza related acute respiratory failure with high mortality rates [33]. In COVID-19 associated pulmonary aspergillosis (CAPA) case definition is absent, although recently an expert panel proposed a classification for IAPA, which was used to classify CAPA [14]. Pathophysiology of CAPA consists of lung damage with bilateral alveolar-interstitial damage due to viral replication and cytokine storm in combination with marked low T-lymphocytes CD4 + T and CD8 + T cells [27]. Secondary infection due to lung tissue damage develop within a median of 17 days [34]. CAPA data are scarce but increasingly reported, although histological confirmation is still absent [9,13,35,36]. Of the first 31 COVID-19 patients admitted to our ICU, six where highly suspected for COVID-19 associated pulmonary aspergillosis (CAPA) [9]. In this case series, BAL fluid galactomannan was positive in six out of the seven cases, concluding in the clinical diagnosis of probable CAPA."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T213","span":{"begin":0,"end":209},"obj":"Sentence"},{"id":"T214","span":{"begin":210,"end":323},"obj":"Sentence"},{"id":"T215","span":{"begin":324,"end":534},"obj":"Sentence"},{"id":"T216","span":{"begin":535,"end":723},"obj":"Sentence"},{"id":"T217","span":{"begin":724,"end":936},"obj":"Sentence"},{"id":"T218","span":{"begin":937,"end":1023},"obj":"Sentence"},{"id":"T219","span":{"begin":1024,"end":1136},"obj":"Sentence"},{"id":"T220","span":{"begin":1137,"end":1278},"obj":"Sentence"},{"id":"T221","span":{"begin":1279,"end":1422},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Recently there is increasing awareness and concern for development of secondary infection in COVID patients e.g. invasive aspergillus co-infection, a contra-indication for (long-term) systemic steroid therapy. Criteria and risk factors for invasive pulmonary aspergillosis are well defined in immunocompromised populations. Furthermore it is a well known complication of severe influenza pneumonia with reported incidences of 19% in ICU patients admitted for influenza related acute respiratory failure with high mortality rates [33]. In COVID-19 associated pulmonary aspergillosis (CAPA) case definition is absent, although recently an expert panel proposed a classification for IAPA, which was used to classify CAPA [14]. Pathophysiology of CAPA consists of lung damage with bilateral alveolar-interstitial damage due to viral replication and cytokine storm in combination with marked low T-lymphocytes CD4 + T and CD8 + T cells [27]. Secondary infection due to lung tissue damage develop within a median of 17 days [34]. CAPA data are scarce but increasingly reported, although histological confirmation is still absent [9,13,35,36]. Of the first 31 COVID-19 patients admitted to our ICU, six where highly suspected for COVID-19 associated pulmonary aspergillosis (CAPA) [9]. In this case series, BAL fluid galactomannan was positive in six out of the seven cases, concluding in the clinical diagnosis of probable CAPA."}

LitCovid-PMC-OGER-BB

2_test

{"project":"2_test","denotations":[{"id":"32674001-30076119-58631480","span":{"begin":530,"end":532},"obj":"30076119"},{"id":"32674001-32192578-58631481","span":{"begin":932,"end":934},"obj":"32192578"},{"id":"32674001-32171076-58631482","span":{"begin":1019,"end":1021},"obj":"32171076"},{"id":"32674001-32339350-58631483","span":{"begin":1129,"end":1131},"obj":"32339350"}],"text":"Recently there is increasing awareness and concern for development of secondary infection in COVID patients e.g. invasive aspergillus co-infection, a contra-indication for (long-term) systemic steroid therapy. Criteria and risk factors for invasive pulmonary aspergillosis are well defined in immunocompromised populations. Furthermore it is a well known complication of severe influenza pneumonia with reported incidences of 19% in ICU patients admitted for influenza related acute respiratory failure with high mortality rates [33]. In COVID-19 associated pulmonary aspergillosis (CAPA) case definition is absent, although recently an expert panel proposed a classification for IAPA, which was used to classify CAPA [14]. Pathophysiology of CAPA consists of lung damage with bilateral alveolar-interstitial damage due to viral replication and cytokine storm in combination with marked low T-lymphocytes CD4 + T and CD8 + T cells [27]. Secondary infection due to lung tissue damage develop within a median of 17 days [34]. CAPA data are scarce but increasingly reported, although histological confirmation is still absent [9,13,35,36]. Of the first 31 COVID-19 patients admitted to our ICU, six where highly suspected for COVID-19 associated pulmonary aspergillosis (CAPA) [9]. In this case series, BAL fluid galactomannan was positive in six out of the seven cases, concluding in the clinical diagnosis of probable CAPA."}

PMC:7340597 / 25705-27127 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7340597 / 25705-27127 JSON TXT